SCHEMBL5784282

SCHEMBL5784282

CCOC(=O)C(NC(=O)c1ccc(OC)nc1)C(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.50
GABRA1 P14867 2/20 0.49
GABRA5 P31644 3/20 0.46
MAPT P10636 3/20 0.46
CXCR1 P25024 1/20 0.46
CXCR2 P25025 1/20 0.46
CTSA P10619 1/20 0.45
GRN P28799 2/20 0.45
SORT1 Q99523 2/20 0.45
NR1I2 O75469 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2C9 P11712 1/20 0.44
IDO1 P14902 1/20 0.44
CYP2C19 P33261 1/20 0.44
KCNH2 Q12809 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.43
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5782817 0.85 HDAC1 (0.55) GABRA1GABRA5MAPTKDM4EMEN1
SCHEMBL20812214 0.81 NNMT (0.60) NNMTGABRA1GABRA5GRNSORT1
SCHEMBL702548 0.80 TAS1R3 (0.63) NNMTGABRA1GRNSORT1
SCHEMBL5784288 0.79 GRN (0.44) NNMTGABRA1GABRA5MAPTCTSA
SCHEMBL5424180 0.79 TAS1R3 (0.61) MAPTRAB9AKDM4EMEN1KMT2A
SCHEMBL23628709 0.78 GABRA5 (0.56) NNMTGABRA1GABRA5GRNSORT1
SCHEMBL3436035 0.78 GRN (0.50) NNMTGABRA1GABRA5GRNSORT1
SCHEMBL10972399 0.78 NNMT (0.60) NNMTMAPTCYP2C9CYP2C19MKNK1
SCHEMBL1882423 0.76 NNMT (0.67) NNMTGABRA1MAPTCXCR1CXCR2
SCHEMBL5782189 0.76 KMT2A (0.54) MAPTRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 NNMT 3741/4885GABRA1 2974/4885GABRA5 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.